RT Journal Article
SR Electronic
T1 Duration of Viral Clearance in IDF Soldiers with Mild COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.28.20116145
DO 10.1101/2020.05.28.20116145
A1 Tomer Talmy
A1 Adili Tsur
A1 Or Shabtay
YR 2020
UL http://medrxiv.org/content/early/2020/05/31/2020.05.28.20116145.abstract
AB Policies determining the duration of quarantine and return to work for confirmed COVID-19 patients still lack evidence. We report our findings regarding the duration of viral RNA positivity among a cohort of young patients with mild disease. Between March 20th, 2020, and May 10th, 2020, 219 soldiers were admitted to the Israel Defense Forces Medical Corps (IDF-MC) COVID-19 rehabilitation center following a positive RT-PCR test for SARS-CoV-2. 119 of these patients, 84 (70.6%) males, 35 (29.4%) females with a median age of 21 (IQR 19-25) were classified as having mild disease and had two consecutive negative RT-PCR tests by May 10th, 2020. The median time for SARS-CoV-2 positivity in nasopharyngeal or oropharyngeal swabs in the study population was 21 days (IQR 15-27) from symptom onset, with a range of 4 to 45 days. The results of this study suggest that in young and healthy adult patients with COVID-19, the median duration of viral positivity is around three weeks. This duration is higher than previously reported in other populations. Young and healthy adults comprise much of the population workforce, and the results of this study may assist in determining the isolation period for symptomatic adults and confirmed COVID-19 patients with mild symptoms. Further studies on this topic should look to expand and determine the intervals of serial testing for confirmed patients and determine the duration of SARS-CoV-2 positivity in other populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding available.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the IDF-MC institutional ethics committee, which waived the requirement for informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFull patient data cannot be disclosed due to data security policies in the IDF. Deidentified data including patient clinical data is available per request.